Overall, the prevalence of HIV associated neurocognitive disorders (HAND) in the study was 70.37%.
Assessment of neurocognitive disorders in HIV infected patients receiving combination of anti-retroviral therapy at a tertiary care hospital - An observational study
Shwetha S, Rebecca Elizabeth Chacko, Dr. Blessy K George, Dr. Balakeshwa Ramaiah, Dr. Shirley James
- Editor approved · 16 Nov 2026
- April 2023
- DOI 10.56511/jipbs.2023.10201
The question
How common are HIV associated neurocognitive disorders (HAND) in people living with HIV who are on combination antiretroviral therapy, and how do the MMSE and IHDS scales compare in assessing them?
- Combination antiretroviral therapy has improved life expectancy for people living with HIV, yet HAND is still prevalent.
- The authors note that the therapy itself could be one of the associated factors.
- The study also aimed to work out the risk factors associated with HAND.
What was done
- A case-control study: 27 HIV negative controls and 54 people living with HIV who were on combination antiretroviral therapy.
- Their neurocognition was screened with two neuropsychological tests, the MMSE and the IHDS.
- Each person living with HIV was then placed in one stage: HIV Associated Dementia (HAD), Mild Neurocognitive Impairment (MND) or Asymptomatic Neurological Impairment (ANI).
Key findings
For the specific HAND diagnoses, the prevalence estimates were 57.89% for Asymptomatic Neurological Impairment, 28.9% for Mild Neurocognitive Impairment and 13.1% for HIV Associated Dementia.
The IHDS showed a good ability to screen for HAND: with 10 as the optimal cut-off score, its sensitivity was high at 70% and its specificity minimal.
The study reports as strongly correlated: age, male gender, low literacy, the presence of comorbidities, the severity of the disease and a therapy regimen with a low CNS penetration effectiveness (CPE) score.
Why it matters
- The authors suggest that the IHDS is a better tool for HAND screening, with greater sensitivity, and that it can help further cognitive evaluation.
- According to the authors, the overall prevalence was equivalent to what recently reported studies found.
How to cite
Shwetha S, Rebecca Elizabeth Chacko, Dr. Blessy K George, Dr. Balakeshwa Ramaiah, Dr. Shirley James. Assessment of neurocognitive disorders in HIV infected patients receiving combination of anti-retroviral therapy at a tertiary care hospital - An observational study. Journal of Innovations in Pharmaceutical and Biological Sciences. 2023;10(02):01-07. https://doi.org/10.56511/jipbs.2023.10201
- The article at doi.org (the publisher's page and PDF)
- The article on the journal's site
- The journal at the ISSN Portal (ISSN 2349-2759)